LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

The Gr8 Eye Movement campaign by Prevent Blindness and Regeneron emphasizes the critical role of caregivers in eye health, revealing significant gaps in caregivers' awareness of retinal diseases and ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...

A program from National Health Service (NHS) England will bring optical coherence tomography (OCT) scans “closer to home” for thousands of patients. As part of an effort to improve outcomes for ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured ...

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...